Wolfgang Kintzel New CEO at Cellbox Solutions
Wolfgang Kintzel has an extensive background in extracting full business potential of innovative products in international markets. He served in various positions as business leader in global organizations, such as Schering AG (Berlin) and Tyco Healthcare (US), as well as in a startup environment, such as at amaxa AG (Cologne). Wolfgang is credited with building and nurturing true start up organizations from the early seed stage to successful exit with M&A value in total over €200 M. He holds several board seats in European companies. Wolfgang has a Master’s degree in biology from Ruhr University, Bochum as well as a degree in Finance and Leadership from University St Gallen, Switzerland.
"Wolfgang Kintzel is the ideal person for Cellbox at this important juncture in its growth. His pivotal role in building highly successful companies paired with his impressive expertise in all areas of business leadership, with a focus on sales & marketing combined with an extensive background in corporate development form the skill set that is required to move Cellbox Solutions to the next level of success and to grow the company into a streamlined BioMedTech champion,” stated Adlkofer.
“Cellbox Solutions is a truly innovative and exciting, mission-focused start up. Based on technology developed initially at the German “Fraunhofer Institute,” the novel Cellbox products meet the challenges in transporting biological sample, gene-therapy products, therapeutic cells and more under fully monitored and controlled temperature and CO2 conditions,” stated Kintzel.
Strong International expansion efforts, in addition the commercial launch of Cellbox, define the strategic pathway of Cellbox Solutions for 2020/2021. The new leadership team will continue to drive execution with clear priorities to achieve excellence through global cooperation and by specifically addressing the areas of sales, product innovation and corporate growth.
Biotech & Pharma, MedTech
Eppendorf steigert 2021 Umsatz auf 1,1 Mrd. Euro
Biotech & Pharma, Forschung & Hochschulen , LSN